Intrathecal cyclodextrin therapy of feline Niemann-Pick type C disease
鞘内环糊精治疗猫 C 型尼曼匹克病
基本信息
- 批准号:8629803
- 负责人:
- 金额:$ 34.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-04-01 至 2016-03-31
- 项目状态:已结题
- 来源:
- 关键词:Action PotentialsAddressAdolescentAffectAgeAtaxiaAuditory systemBiochemicalBiochemical MarkersBiological MarkersBiological ModelsBlood - brain barrier anatomyBrain DiseasesBrain PathologyCentral Nervous System DiseasesCessation of lifeChildCholesterolCholesterol HomeostasisClinicalClinical TrialsControlled StudyCyclodextrinsDataDementiaDiseaseDisease ProgressionDoseDrug KineticsDrug effect disorderEthicsEvaluationFamily FelidaeFelis catusGliosisHearingHeterogeneityHumanImageLiver diseasesLongitudinal StudiesLung diseasesMeasuresMethodsMissense MutationModelingMonitorMusMutationN-acetylaspartateNeurologicNeuronsNuclear Magnetic ResonanceOrphan DrugsOutcomePathogenesisPathologyPatientsPharmacologyPharmacotherapyPlasmaProteinsRegulationSample SizeSeverity of illnessSphingosineSubarachnoid SpaceSupraoptic Vertical OphthalmoplegiaSurrogate MarkersSwellingTechniquesTestingTherapeuticToxic effectTreatment EfficacyTreatment outcomeTryptophanbasecalbindindisease-causing mutationin vivoinnovationinsightnervous system disorderneuron lossneurotoxicototoxicitypublic health relevanceremediation
项目摘要
DESCRIPTION (provided by applicant): Niemann-Pick type C (NPC) disease is a progressive neurological disorder of children characterized by dementia, ataxia, and death typically within the first or second decade. Despite the identification of over 300 causative mutations, therapies to successfully treat NPC disease have been ineffective to date. 2- hydroxypropyl-ss-cyclodextrin (HPssCD), an FDA-designated orphan drug (May 2010), is now being administered to a small number of children with NPC disease based on favorable treatment outcome data in subcutaneously treated npc1-/- mice and cats. However, due to the small patient sample size and the inability to undertake control studies in normal children for ethical reasons, the mechanisms of drug action and potential toxicity cannot be addressed in human patients. We propose to rigorously evaluate the pharmacologic, mechanistic, and toxicity issues in the feline model which has a spontaneously-occurring missense mutation in NPC1 (2864G-C) orthologous to the most common mutation in the most common form of NPC disease in patients and disease progression which recapitulates the neuropathological and biochemical abnormalities observed in these patients. Using the feline model, we achieved highly encouraging results following intrathecal HPssCD administration in that clinical neurological signs of disease were completely resolved at least up to 24 weeks of age (an age when untreated cats die), however, we identified a completely unanticipated dose-related toxic effect on the auditory system. We will utilize our highly innovative feline model to further evaluate disease pathogenesis and the therapeutic efficacy of HPssCD via the following aims: Specific Aim 1. Determine whether the CSF concentration of HPssCD predicts amelioration of NPC-related neurological disease and produces ototoxicity. Specific Aim 2. Identify sensitive and predictive biomarkers of neurological disease to monitor disease progression and treatment efficacy and provide insight into pathogenesis. Specific Aim 3. Evaluate non-invasive nuclear magnetic resonance (NMR) measures of brain disease progression and treatment efficacy.
描述(由申请人提供):尼曼-皮克C型(NPC)病是一种进行性儿童神经系统疾病,以痴呆、共济失调和死亡为特征,通常发生在第一个或第二个十年。尽管已经发现了300多种致病突变,但迄今为止,成功治疗鼻咽癌的疗法仍是无效的。2-羟丙基-ss-环糊精(HPssCD)是fda指定的孤儿药(2010年5月),基于皮下治疗的npc1-/-小鼠和猫的良好治疗结果数据,目前正在用于少数患有NPC疾病的儿童。然而,由于患者样本量小,并且由于伦理原因无法在正常儿童中进行对照研究,因此无法在人类患者中研究药物作用机制和潜在毒性。我们建议严格评估猫模型的药理学、机制和毒性问题,该模型具有NPC1 (2864G-C)自发发生的错感突变,该突变与患者中最常见的鼻咽癌疾病中最常见的突变同源,并且疾病进展概括了这些患者中观察到的神经病理和生化异常。使用猫模型,我们取得了非常令人鼓舞的结果,在鞘内给予HPssCD后,疾病的临床神经症状至少在24周龄(未经治疗的猫死亡的年龄)完全解决,然而,我们发现了完全出乎意料的剂量相关的听觉系统毒性作用。我们将利用我们高度创新的猫模型,通过以下目标进一步评估HPssCD的疾病发病机制和治疗效果:确定HPssCD的脑脊液浓度是否预测npc相关神经系统疾病的改善和产生耳毒性。具体目标2。识别神经系统疾病的敏感和预测性生物标志物,以监测疾病进展和治疗效果,并提供发病机制的见解。具体目标3。评估非侵入性核磁共振(NMR)测量脑疾病进展和治疗效果。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHARLES H VITE其他文献
CHARLES H VITE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHARLES H VITE', 18)}}的其他基金
AAV-Mediated Gene Therapy for CNS Disease Correction in Feline NPC1 Disease
AAV 介导的基因治疗可纠正猫科动物 NPC1 疾病的中枢神经系统疾病
- 批准号:
10402089 - 财政年份:2021
- 资助金额:
$ 34.65万 - 项目类别:
AAV-mediated gene therapy for CNS disease correction in feline NPC1 disease
AAV 介导的基因治疗可纠正猫科动物 NPC1 疾病的中枢神经系统疾病
- 批准号:
10524751 - 财政年份:2020
- 资助金额:
$ 34.65万 - 项目类别:
AAV-mediated gene therapy for CNS disease correction in feline NPC1 disease
AAV 介导的基因治疗可纠正猫科动物 NPC1 疾病的中枢神经系统疾病
- 批准号:
10317121 - 财政年份:2020
- 资助金额:
$ 34.65万 - 项目类别:
AAV-mediated gene therapy for CNS disease correction in feline NPC1 disease
AAV 介导的基因治疗可纠正猫科动物 NPC1 疾病的中枢神经系统疾病
- 批准号:
10643054 - 财政年份:2020
- 资助金额:
$ 34.65万 - 项目类别:
Combination Therapy, Biomarkers, and Imaging in Canine Krabbe Disease
犬克拉伯病的联合治疗、生物标志物和影像学
- 批准号:
9080156 - 财政年份:2016
- 资助金额:
$ 34.65万 - 项目类别:
Intrathecal cyclodextrin therapy of feline Niemann-Pick type C disease
鞘内环糊精治疗猫 C 型尼曼匹克病
- 批准号:
8447003 - 财政年份:2011
- 资助金额:
$ 34.65万 - 项目类别:
Intrathecal cyclodextrin therapy of feline Niemann-Pick type C disease
鞘内环糊精治疗猫 C 型尼曼匹克病
- 批准号:
8084588 - 财政年份:2011
- 资助金额:
$ 34.65万 - 项目类别:
Intrathecal cyclodextrin therapy of feline Niemann-Pick type C disease
鞘内环糊精治疗猫 C 型尼曼匹克病
- 批准号:
8820838 - 财政年份:2011
- 资助金额:
$ 34.65万 - 项目类别:
Intrathecal cyclodextrin therapy of feline Niemann-Pick type C disease
鞘内环糊精治疗猫 C 型尼曼匹克病
- 批准号:
8235857 - 财政年份:2011
- 资助金额:
$ 34.65万 - 项目类别:
相似海外基金
Enhancing Structural Competency in School-Based Health Centers to Address LGBTQ+ Adolescent Health Equity
增强校本健康中心的结构能力,以解决 LGBTQ 青少年健康公平问题
- 批准号:
10608426 - 财政年份:2023
- 资助金额:
$ 34.65万 - 项目类别:
Application and feasability of a brief digital screening tool to address parental and adolescent tobacco and electronic cigarette use in pediatric medical care - a pilot study
简短的数字筛查工具的应用和可行性,以解决儿科医疗中父母和青少年烟草和电子烟的使用问题 - 一项试点研究
- 批准号:
486580 - 财政年份:2022
- 资助金额:
$ 34.65万 - 项目类别:
Studentship Programs
Co-design of an intervention to address alcohol use among adolescent boys and young men in Tanzania
共同设计一项干预措施,解决坦桑尼亚青春期男孩和年轻男性的饮酒问题
- 批准号:
MR/V032380/1 - 财政年份:2022
- 资助金额:
$ 34.65万 - 项目类别:
Research Grant
Complex intervention to optimise adolescent BMI pre-conception to address the double burden of malnutrition: A RCT in rural and urban South Africa
优化青少年孕前体重指数以解决营养不良的双重负担的复杂干预措施:南非农村和城市的随机对照试验
- 批准号:
MR/V005790/1 - 财政年份:2021
- 资助金额:
$ 34.65万 - 项目类别:
Research Grant
Application of a brief digital screening tool to address parental and adolescent tobacco and electronic cigarette use in pediatric medical care
应用简短的数字筛查工具来解决儿科医疗中父母和青少年烟草和电子烟的使用问题
- 批准号:
455984 - 财政年份:2021
- 资助金额:
$ 34.65万 - 项目类别:
Operating Grants
Complex intervention to optimise adolescent BMI pre-conception to address the double burden of malnutrition: A RCT in rural and urban South Africa
优化青少年孕前体重指数以解决营养不良的双重负担的复杂干预措施:南非农村和城市的随机对照试验
- 批准号:
MR/V005790/2 - 财政年份:2021
- 资助金额:
$ 34.65万 - 项目类别:
Research Grant
Development of the Cannabis Actions and Practices (CAP): A Parent-Focused Intervention to Address Adolescent Marijuana Use
大麻行动和实践 (CAP) 的发展:以家长为中心的干预措施,解决青少年大麻使用问题
- 批准号:
10057761 - 财政年份:2020
- 资助金额:
$ 34.65万 - 项目类别:
Development of the Cannabis Actions and Practices (CAP): A Parent-Focused Intervention to Address Adolescent Marijuana Use
大麻行动和实践 (CAP) 的发展:以家长为中心的干预措施,解决青少年大麻使用问题
- 批准号:
10213683 - 财政年份:2020
- 资助金额:
$ 34.65万 - 项目类别:
Targeted interventions to address the multi-level effects of gender-based violence on PrEP uptake and adherence among adolescent girls and young women in Kenya
有针对性的干预措施,以解决性别暴力对肯尼亚少女和年轻妇女接受和坚持 PrEP 的多层面影响
- 批准号:
9403567 - 财政年份:2017
- 资助金额:
$ 34.65万 - 项目类别:
Designing targeted interventions to address HIV vulnerabilities and improve clinical outcomes among conflict affected adolescent girls and young women under 25 in Northern Uganda
设计有针对性的干预措施,以解决乌干达北部受冲突影响的少女和 25 岁以下年轻妇女的艾滋病毒脆弱性并改善临床结果
- 批准号:
356145 - 财政年份:2016
- 资助金额:
$ 34.65万 - 项目类别:
Operating Grants